RT @mchaudhry82: Monday’s Watch 1 $AAPL $AMZN $FB $AMD $BTC.X $ETH.X $ADBE $BA $BABA $BIDU $BLK $CELG $COUP $CRM $EA $EXPE $AKER $ABBV $BMY…
RT @mchaudhry82: Monday’s Watch 1 $AAPL $AMZN $FB $AMD $BTC.X $ETH.X $ADBE $BA $BABA $BIDU $BLK $CELG $COUP $CRM $EA $EXPE $AKER $ABBV $BMY…
RT @mchaudhry82: Monday’s Watch 1 $AAPL $AMZN $FB $AMD $BTC.X $ETH.X $ADBE $BA $BABA $BIDU $BLK $CELG $COUP $CRM $EA $EXPE $AKER $ABBV $BMY…
$EFTM 006? Many laughed @ $TSLA as a #startup this electric car co UNKNOWN $BAC $GE $BMY $WFC $MU $YNDX $AMD $OCLR… https://t.co/Z5kT50BYb6
#AI is the best way to generate #tradeideas - click here https://t.co/QNcRhVURwB $BMY, $BIIB, $AMGN, $ABX, $GLD,… https://t.co/nKyySXlMbK
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @adamfeuerstein: A controversial #ASCO18 presentation underscores risk $BMY $NKTR carry with experimental cancer drug https://t.co/QKzGs…
$BMY
Investor call from ASCO conf
8:30PM
https://t.co/HVbOEQoH6I
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @BioStocks: The hype over cancer-drug combos has dramatically outpaced delivery. https://t.co/4YAiAoIGM5 #ASCO18 $MRK $BMY $INCY $JNCE
RT @matthewherper: Nektar And Bristol Hurtle Forward With Experimental Cancer Drug $NKTR $BMY #ASCO18 https://t.co/AX5rv4PW20
RT @adamfeuerstein: A controversial #ASCO18 presentation underscores risk $BMY $NKTR carry with experimental cancer drug https://t.co/QKzGs…
$MRK $BMY more I look at results more am convinced keytruda and opdivo are the same. https://t.co/d1cEYqTWn7
$NKTR, $BMY Reveal Preliminary Findings from Study Testing NKTR-214 in Combination with Opdivo (nivolumab) in Patie… https://t.co/tQ6nIvRvfH
Monday’s Watch 1 $AAPL $AMZN $FB $AMD $BTC.X $ETH.X $ADBE $BA $BABA $BIDU $BLK $CELG $COUP $CRM $EA $EXPE $AKER… https://t.co/0Ku5A05GqU
RT @StocksThatDoubl: https://t.co/uAcamNRUPt alerted $HMNY +1366% https://t.co/iMYklIJgv0 MUST See Track Record $CWBR $CRMD $CNTF $WMLP $CA…
$CNAT $CWBR $MDGL $CBAY $ENTA $IMRN $GALT $SNY $SHPG $NVS $BMY $PFI https://t.co/ewDnSOqPxd
RT @jodigralnick: SET YOUR ALARM: our kick-#ASCO LIVE coverage starts tomorrow on @SquawkCNBC, with $CELG CEO at 710amET and $BMY CEO at 81…
RT @ChrisLacoursier: @cnbc #CNBC @MadMoneyOnCNBC can executive producers comment on names mentioned in this article #biotech $NWBO $BMY @m…
RT @ChrisLacoursier: @cnbc #CNBC @MadMoneyOnCNBC can executive producers comment on names mentioned in this article #biotech $NWBO $BMY @m…
https://t.co/uAcamNRUPt alerted $HMNY +1366% https://t.co/iMYklIJgv0 MUST See Track Record $CWBR $CRMD $CNTF $WMLP… https://t.co/JAbpgaTIR4
RT @adamfeuerstein: Dear $NKTR & $BMY —
Maybe you should have run a simple and reliable randomized, controlled clinical trial?
Sincerely,…
RT @adamfeuerstein: A controversial #ASCO18 presentation underscores risk $BMY $NKTR carry with experimental cancer drug https://t.co/QKzGs…
RT @matthewherper: Merck Wins Again #ASCO18
https://t.co/ME3T7EO46I
$MRK $BMY $AZN $ROG
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @jodigralnick: SET YOUR ALARM: our kick-#ASCO LIVE coverage starts tomorrow on @SquawkCNBC, with $CELG CEO at 710amET and $BMY CEO at 81…
SET YOUR ALARM: our kick-#ASCO LIVE coverage starts tomorrow on @SquawkCNBC, with $CELG CEO at 710amET and $BMY CEO… https://t.co/K9PCINPxTj
@Biomaven It wouldn’t be the first time Big Pharma gave up and away a drug, $BMY gave Cabo back to $EXEL
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
Join https://t.co/uAcamNRUPt for alerts like this $RPRX +170% https://t.co/7uWekI8Rdq $YUMA $MTSL $BGI $WMLP $WHZT… https://t.co/k7luzLVHz9
RT @AntounNabhan: Multiple myeloma is a good example where high pricing (e.g. thalomid) incentivized lots of research. Payoff is >10 years…
Multiple myeloma is a good example where high pricing (e.g. thalomid) incentivized lots of research. Payoff is >10… https://t.co/wEKkTnHa5R
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
Top 5 LT momentum stocks of the S&P 100:$MON $AMZN $FB $AAPL $MA
Bottom 5:$CELG $CHTR $MO $BMY… https://t.co/vEIAwtG56e
RT @ChrisLacoursier: @cnbc #CNBC @MadMoneyOnCNBC can executive producers comment on names mentioned in this article #biotech $NWBO $BMY @m…
RT @ChrisLacoursier: @cnbc #CNBC @MadMoneyOnCNBC can executive producers comment on names mentioned in this article #biotech $NWBO $BMY @m…
RT @jodigralnick: TUNE IN TOMORROW: most of the major newsmakers at #ASCO18 are joining @megtirrell LIVE and EXCLUSIVE on @CNBC: $CELG, $BM…
RT @BioStocks: $MRK cements its position as dominant developer of immunotherapy https://t.co/2FESs9d6R0 $BMY $AZN #ASCO18
@Ogut_Ozgur Re 3): It's reasonable 2b skeptical, and the anecdotal reports from Dr. Gettinger even sounded like pro… https://t.co/VuGjGHxwKA
From $NKTR ASCO Q&A: 1) Is there a general difference between Keytruda & Opdivo? 2) Is there a general difference b… https://t.co/6YoQX01bGc
RT @gcbioinv: $MRK discussant comparing $BMY trial to KN-042, imbalance in Nivo trial in PD-L1 expression, crossover allowance likely major…
RT @AndyBiotech: $BMY #AACR18 CheckMate-568 for identification of TMB cutoff for Nivo+Ipi combo in 1L NSCLC
https://t.co/SULzxTVegf
TMB…
RT @BioStocks: $MRK cements its position as dominant developer of immunotherapy https://t.co/2FESs9d6R0 $BMY $AZN #ASCO18
RT @matthewherper: Merck Wins Again #ASCO18
https://t.co/ME3T7EO46I
$MRK $BMY $AZN $ROG
If you don't consistently find trades like $SDRL +186%, then https://t.co/uAcamNRUPt https://t.co/h0RvHOXtno $CLWT… https://t.co/MWPYxblW7y
RT @adamfeuerstein: A controversial #ASCO18 presentation underscores risk $BMY $NKTR carry with experimental cancer drug https://t.co/QKzGs…
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
Why didn't they just do a right trial so we all could interpret results? $BMY's scientific standard has sunk to be… https://t.co/xlv9rjGG5Y
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
Make-or-break SITC coming up this fall for $BMY and $NKTR. Will be fun to watch! https://t.co/kDnqZd0Euo
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @gcbioinv: $MRK discussant comparing $BMY trial to KN-042, imbalance in Nivo trial in PD-L1 expression, crossover allowance likely major…
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @ChrisLacoursier: @cnbc #CNBC @MadMoneyOnCNBC can executive producers comment on names mentioned in this article #biotech $NWBO $BMY @m…
Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https://t.co/WEGqDXI0gx
@Thorgood agreed. crowded space. ive been in $GALT for a while as well as $SNY holding $NVS and $BMY options...JAN19 expiries.
Commented on $ADAP $APLN $AUTL $BLCM $BLUE $BMY $CELG $GALT $GILD $IOVA $MBIO $MRK $NKTR $NVS $RHHBY $SGEN $TPIV… https://t.co/yk7izdUCZ0
Commented on $ICPT $AGN $BMY $CEMP $CNAT $CVC $ENTA $GALT $GLMD $GNFTF $MDGL $MNOV $NVO $NVS $RGLS $RHHBY $SHPG… https://t.co/VGqIMvtiME
RT @breckskifan: Commented on $ADAP $APLN $AUTL $BLCM $BLUE $BMY $CELG $GALT $GILD $IOVA $MBIO $MRK $NKTR $NVS $RHHBY $SGEN $TPIV $UMRX htt…
RT @breckskifan: Commented on $ADAP $APLN $AUTL $BLCM $BLUE $BMY $CELG $GALT $GILD $IOVA $MBIO $MRK $NKTR $NVS $RHHBY $SGEN $TPIV $UMRX htt…
Commented on $ADAP $APLN $AUTL $BLCM $BLUE $BMY $CELG $GALT $GILD $IOVA $MBIO $MRK $NKTR $NVS $RHHBY $SGEN $TPIV… https://t.co/dO3XdU74ZK
2018-06-01 Short sale volume (not short interest) for $AMGN is 63%. https://t.co/udZXOA7QoF $PFE 72% $JNJ 33% $ABBV 42% $BMY 46%
"In 2009, Keytruda was considered such a low priority that it placed on the out-license list... a term sheet valuin… https://t.co/hUaVKT7kzv
RT @HSharma_DRG: Encouraging data released at #ASCO18 for much-awaited NKTR-214 plus nivolumab with ORR 42% #melanoma, 53% #RCC, 60% #uroth…
#ASCO18 Some investors have expressed concern that Nektar and BMS are pitching into an expensive phase 3 program wi… https://t.co/QulP6gAC3B
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
$BMY $NKTR https://t.co/FJhKqmyCtI
$BMY $NKTR https://t.co/1xuVsB2EtP
RT @ByAmyBrown: Sellside consensus from @evaluatepharma for Keytruda sales in 2022 has ballooned by $2.1bn this year, to $12.1bn. Even befo…
RT @ByAmyBrown: Sellside consensus from @evaluatepharma for Keytruda sales in 2022 has ballooned by $2.1bn this year, to $12.1bn. Even befo…
RT @JohnCendpts: Nektar wants everyone to stay calm as they carry on with NKTR-214, hoping to avoid an #ASCO18 stampede
$NKTR $BMY
https:/…
RT @SAlphaTrending: $AMGN $BMY $CELG $JNJ $MRK $NVS $PFE $PTLA $RHHBY https://t.co/6pdFfVhsku
2018-06-01 Short sale volume (not short interest) for $EQH is 43%. https://t.co/BLZ9bd0v2g $KEY 63% $GRPN 61% $ALDR 61% $BMY 46%
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
Mixed results for Bristol/Nektar combination in cancer trial https://t.co/4sEeJUveYz $BMY down 0.4 pct $NKTR down 18 pct
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @BioStocks: The hype over cancer-drug combos has dramatically outpaced delivery. https://t.co/4YAiAoIGM5 #ASCO18 $MRK $BMY $INCY $JNCE
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing… https://t.co/O50pcgoRNW
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 1… https://t.co/WX8NxeZ2k0
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
@megtirrell @SullyCNBC @CNBC Long $MRK (Keytruda) & sold $BMY (Opdivo) before recent selloff. Also painfully-long $GILD
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
@julesvideo @jimcramer @TheStreet @SKULLY_Tech @genesimmons @3M Julie nice to see your VP #TheStreet @cnbc Please c… https://t.co/nPGhz76vYj
Nektar down 24% premarket on Opdivo + NKTR-214 data $NKTR $BMY https://t.co/deccNzhFaa
Nektar down 24% premarket on Opdivo + NKTR-214 data in melanoma https://t.co/rUjIDos9PR #premarket $NKTR $BMY
A controversial #ASCO18 presentation:
$NKTR and $BMY are carrying a very expensive and risky program to test their… https://t.co/EvNhn6Yaxm
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
$BMY Opdivo Plus Chemo Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Pati… https://t.co/aAcDzyG6yn
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
$BMY Bristol-Myers Squibb - Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemoth
From our Stock News Alerts App
RT @fezziwig2008: #ASCO18 $MRK Keytruda succeeds in #LungCancer but Fails in #GastricCancer - 2nd Line vs Paclitaxel- showed a trend but No…
RT @FierceBiotech: #ASCO18 Some investors have expressed concern that Nektar and BMS are pitching into an expensive phase 3 program with a…
RT @adamfeuerstein: A controversial #ASCO18 presentation underscores risk $BMY $NKTR carry with experimental cancer drug https://t.co/QKzGs…
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
RT @BioStocks: The hype over cancer-drug combos has dramatically outpaced delivery. https://t.co/4YAiAoIGM5 #ASCO18 $MRK $BMY $INCY $JNCE
RT @megtirrell: Good morning from #ASCO18! Tune in to @CNBC for our interviews w $CELG $BMY $AZN $LOXO $MRK $BPMC $RHHBY (channel 13 at McC…
Preliminary data on Jounce Therapeutics' lead candidate JTX-2011 fails to excite inves... https://t.co/oX7GeOBZik #premarket $JNCE $BMY $MRK
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @megtirrell: Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BP…
RT @megtirrell: Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BP…
RT @megtirrell: Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BP…
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
RT @BioStocks: $MRK cements its position as dominant developer of immunotherapy https://t.co/2FESs9d6R0 $BMY $AZN #ASCO18
Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BPMC $NKTR $GHDX
RT @megtirrell: Early #ASCO18 movers:
$BLUE -5.9%
$BPMC -3.6%
$MRK +1.2%
$BMY -0.4%
$NKTR -17%
Light volume, $LOXO not yet showing pre-mark…
Face it, $MRK Keytruda outdone $BMY Opdivo in most combo tests
RT @megtirrell: Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BP…
$BMY Need to sell my options. I see no light end-the-tunnel.
Buying $MRK instead grudgingly!
RT @fezziwig2008: @ByJonGardner $NKTR 214 now with additional 3 Hyperprogressions -in Melanoma when there was only 1 in RCC in prior presen…
RT @fezziwig2008: In same population RCC $MRK Keytruda/Lenvatinib was awarded BD for 63.3% ORR https://t.co/QhMIYNtEDc while $NKTR $BMY ORR…
$NKTR got or is getting a lot of money from $BMY. Should be a floor in the stock somewhere around here.
RT @megtirrell: Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BP…
RT @megtirrell: Catching up on #ASCO18 out of the weekend? Here's what you need to know: https://t.co/z0NUvEoVoe $MRK $BMY $RHHBY $LOXO $BP…
$BMY announces new #NSCLC data from Phase 3 combo trial at #ASCO18 #LungCancer
$BMY: GapDN 1.10[-2.1%,fill:32%], PrvCl:53.13, PrvLo:52.70, NearCl:BrkPHi[-1.5%], 5:3Accel-, tf:1000000, bigFlt:1.6B, p$vol:73.09M
RT @jodigralnick: Up next from #ASCO18: @bmsnews $BMY CEO joins @megtirrell live and exclusive, 810amET on @SquawkCNBC
$BMY: Bristol-Myers: FDA lifts partial clinical hold on Opdivo based combination study in multiple myeloma https://t.co/axxV7I4pwm
RT @ChrisLacoursier: @julesvideo @jimcramer @TheStreet @SKULLY_Tech @genesimmons @3M Julie nice to see your VP #TheStreet @cnbc Please comm…
Up next from #ASCO18: @bmsnews $BMY CEO joins @megtirrell live and exclusive, 810amET on @SquawkCNBC
RT @odibro: $BMY Opdivo Plus Chemo Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD…
Bristol-Myers Squibb reports PFS data for Opdivo, chemotherapy combination in lung cancer https://t.co/QrQ30CJ2WX $BMY #ASCO18
RT @MarketCurrents: Nektar down 24% premarket on Opdivo + NKTR-214 data in melanoma https://t.co/rUjIDos9PR #premarket $NKTR $BMY
As Micron Technology $MU Share Price Rose, Gibraltar Capital Management Decreased Stake by $4.19 Million; As Bristo… https://t.co/P3fLOzTVhC